| Name | Title | Contact Details |
|---|
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA? (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy.
Calhoun Vision is focused on developing vision correction technologies for post-cataract surgery patients.
Caloptima Health Partnership is a Orange, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Delphinus Medical Technologies, Inc. is an innovation leader in advanced ultrasound development, introducing a dynamic new technique to image the breast with the use of sound and water. Delphinus is committed to creating improved imaging methods that assist medical professionals to better define and diagnose breast disease, while establishing a better patient experience that can be available for all women, regardless of age, without the concern of radiation or pain. Headquartered in Plymouth, MI, Delphinus is the first company to design and manufacture a whole breast ultrasound system that utilizes a ring transducer to transmit and receive ultrasound signals. Known as SoftVue™, three critical sound characteristics are measured and refined through proprietary algorithms, advancing this technology far beyond traditional b-mode ultrasound. By collecting and defining reflection, sound speed, and attenuation data in a 360° orientation, data are gathered and reconstructed in tomographic coronal planes, providing an enriched image set presented for cross-sectional review. SoftVue has received FDA clearance for diagnostic imaging purposes and is not intended for use as a replacement for screening mammography. Delphinus was formed in 2010 as a spin-out of Karmanos Cancer Institute [KCI] in Detroit, MI. Created by Peter Littrup, MD of Karmanos and Neb Duric, PhD of Wayne State University Detroit, MI the SoftVue technology presents a new imaging paradigm in breast disease assessment. Karmanos Cancer Institute has served as a primary investigational site for case collection and clinical studies. Delphinus holds numerous patents and proprietary assets for its innovative and scientifically-advanced works and is poised to usher in a new era of breast imaging.
ClearCorrect works with more than 14,000 doctors, making it a leading manufacturer of clear aligners. The company offers a more affordable and doctor-friendly approach, including a phase-based system to enhance flexibility and control for doctors. It just recently celebrated its 7th year anniversary and has international plans on the horizon.